Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
5,125
Views
32
CrossRef citations to date
0
Altmetric
Research Article

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study

Jingwen Aia Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yi Zhanga Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Haocheng Zhanga Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Qiran Zhanga Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Zhangfan Fua Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Ke Lina Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Jieyu Songa Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yuanhan Zhaoa Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Mingxiang Fana Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Hongyu Wanga Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yang Zhoua Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Xiaohua Chenb Department of Infectious Diseases, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Chao Qiua Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Wenhong Zhanga Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;c National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China;d Key Laboratory of Medical Molecular Virology (MOE/MOH) Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 639-647 | Received 31 Oct 2021, Accepted 31 Dec 2021, Published online: 23 Feb 2022

References

  • See how vaccinations are going in your County and State 2021 [updated October 28]. Available from: https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html.
  • Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021 Dec 7;S1473-3099(21)00681-2.
  • Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine. 2022 Jan 24;40(3):524–530.
  • Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA COVID-19 vaccine among U.S. health care personnel. N Engl J Med. 2021 Dec 16;385(25):e90.
  • Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021 Dec 9;385(24):e83.
  • FDA. Authorizes booster dose of Pfizer-BioNTech COVID-19 Vaccine for certain populations 2021 [updated September 22]. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations.
  • Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 2021. Available from: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization
  • Zhu F, Jin P, Zhu T, et al. Safety and immunogenicity of a recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine with a homologous prime-boost regimen in healthy participants aged ≥6 years: a randomized, double-blind, placebo-controlled, phase 2b Trial. Clinical Infectious Diseases. 2021.
  • Guo W, Duan K, Zhang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine. 2021;38:101010.
  • Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258–2276.
  • Jingxin L, Lihua H, Xiling G, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021 Sep 06. DOI:10.1101/2021.09.03.21263062
  • Early estimates of the effectiveness of booster shots in Chile 2021 [updated October 7]. Available from: https://www.minsal.cl/wp-content/uploads/2021/10/2021-10-07-EFECTIVIDAD-DOSIS-DE-REFUERZO_ENG.pdf.
  • Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686.
  • Jeewandara C, Aberathna IS, Pushpakumara PD, et al. Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv. 2021:2021.07.15.21260621.
  • Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. medRxiv. 2021:2021.09.12.21263373.
  • Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv. 2021:2021.09.02.21261735.
  • Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021 Oct 21;385(17):1627–1629.
  • Atmar RL, Lyke KE, Deming ME, et al. Heterologous SARS-CoV-2 booster vaccinations – preliminary report. medRxiv. 2021:2021.10.10.21264827.
  • Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398(10304):981–990.
  • Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021 Nov;27(11):2032–2040.
  • Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 Jan;21(1):39–51.
  • Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181–192.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.